Table 2.
dp-ucMGP concentrations at baseline and 6-month follow-up by intervention groups.
| N | Baseline dp-ucMGP (pmol/L) | 6-month dp-ucMGP (pmol/L) | Delta dp-ucMGP (pmol/L) | p-Value | |
|---|---|---|---|---|---|
| All study participants | |||||
| Placebo | 65 | 735 ± 638 | 697 ± 609 | −38.5 ± 389 | 0.562 |
| Vitamin D3 | 66 | 651 ± 462 | 655 ± 438 | 4.5 ± 127 | |
| Adjusted result | 29.5 (−64.5, 123) | 0.536 | |||
| No multivitamin and VKA | |||||
| Placebo | 30 | 596 ± 355 | 504 ± 171 | −91.9 ± 359 | 0.125 |
| Vitamin D3 | 40 | 577 ± 311 | 580 ± 277 | 3.0 ± 125 | |
| Adjusted result | 92.8 (5.7, 180) | 0.034 | |||
Values are mean and standard deviation or regression coefficients and 95% confidence adjusted for baseline dp-ucMGP and sex intervals; dp-ucMGP: dephosphorylated uncarboxylated matrix gla protein, VKA: vitamin K antagonist Natural log transformed data yielded similar results.